Exogenus Therapeutics Leads €13M EU Osteoarthritis Project
Cantanhede, Portugal — October 29, 2026 Exogenus Therapeutics announced the launch of ExoCordOA, a five-year, €13 million Horizon Europe-funded...
Regenerative Medicine
Advertisement
PolarityBio to Present Phase 3 SkinTE Data at SAWC Fall 2026
SALT LAKE CITY — September 29, 2026 PolarityBio announced that results from its pivotal Phase 3 COVER DFUS II...
Longeveron Reports ELPIS II Results for Laromestrocel
MIAMI — September 16, 2026 Longeveron Inc. announced topline results from its Phase 2b ELPIS II clinical trial evaluating...
PolarityBio Gains FDA Priority Review for SkinTE in DFUs
SALT LAKE CITY, Utah — September 15, 2026 PolarityBio announced that the U.S. Food and Drug Administration (FDA) has...
Resolution Therapeutics Completes RTX001 EMERALD Enrollment
EDINBURGH and LONDON, UK — September 11, 2026 Resolution Therapeutics Limited announced that the final patient has been treated...
Advertisements
Matricelf Gains FDA Feedback for NewRal Spinal Injury Trial
Ness Ziona, Israel, September 3, 2026 Matricelf Ltd., a regenerative medicine company developing personalized engineered tissue therapies, has received...
FibroBiologics Secures U.S. Patent for Disc Regeneration
Houston, Texas, September 1, 2026 FibroBiologics, Inc. has announced the issuance of a new U.S. patent covering a potential...
Resolution Therapeutics Expands U.S. Access for RTX001
EDINBURGH, UK & LONDON, UK, Sept. 1, 2026 Resolution Therapeutics Limited has partnered with Blood Centers of America, Inc....
Celularity and MuseCell Innovations Announce U.S. Manufacturing Collaboration
Florham Park, New Jersey & Singapore – August 28, 2026 Celularity Inc. announced a new U.S.-based manufacturing collaboration with...
FibroBiologics Gains Australian Patent for Disc Therapy
Houston, Texas, August 20, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing regenerative therapies based on fibroblast cells and...
Advertisement
